Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Biotechnology
US biopharma company Coronado Biosciences has formed a wholly-owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. 8 October 2014
Pharmaceutical
USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal cannabinoid treatments, has named two leading industry veterans to lead the company. 2 October 2014
Pharmaceutical
Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two pivotal Phase III studies of in psoriatic arthritis. 25 September 2014
Biotechnology
The US Food and Drug Administration has approved biotech major Celgene’s Otezla (apremilast), an oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. 24 September 2014
Pharmaceutical
US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker Sun Pharmaceuticals for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222). 17 September 2014
Pharmaceutical
US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster arthritis drug Humira (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. 11 September 2014
Pharmaceutical
New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato(ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased. 4 September 2014
Generics
Perrigo has said it has filed an Abbreviated New Drug Application for desoximetasone topical spray 0.25%, currently marketed as Topicort by Taro. 30 July 2014
Pharmaceutical
The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors of Australian biotech firm Clinuvel Pharmaceuticals, the shares of which rocketed 28% to A$2.15 in mid-morning trading today. 28 July 2014
Pharmaceutical
Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s Ranbaxy Laboratories, granting the latter exclusive right to market, sell and distribute Cipher's acne treatment isotretinoin capsules in Brazil. 25 July 2014
Pharmaceutical
USA-based Anacor Pharmaceuticals has entered into an exclusive agreement with Sandoz, a subsidiary of Swiss drug major Novartis, to distribute and commercialize Anacor’s drug Kerydin (tavaborole) topical solution in the USA, worth a potential $110 million. 22 July 2014
Pharmaceutical
Danish dermatology specialist LEO Pharma and Canada’s KLOX Technologies, both privately-held companies, have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX’s BioPhotonic technology platform in dermatology. 16 July 2014
article
French drugmaker Ipsen and global dermatology and skin health company Galderma have expanded the scope of their neurotoxin partnership. 11 July 2014
Pharmaceutical
Thornton & Ross, the UK subsidiary of German generic and branded drugmaker Stada Arzneimittel, has purchased the production and distribution rights for the Flexitol brand product portfolio in the UK and Ireland. 10 July 2014
Pharmaceutical
Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating psoriasis than etanercept, the drug recommended the UK’s National Institute for Health and Clinical Excellence. 10 July 2014
Pharmaceutical
Canada’s Valeant Pharmaceuticals International and its takeover target Precision Dermatology have agreed to sell or relinquish rights to the latter’s branded single-agent topical tretinoins and generic Retin-A, common acne treatments, to settle Federal Trade Commission charges that Valeant’s proposed $475 million acquisition of Precision would likely be anticompetitive, it was announced on Thursday. 4 July 2014
Pharmaceutical
Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. 3 July 2014
Pharmaceutical
The acne therapeutics market value will undergo steady growth by 2018, increasing from $2.3 billion in 2012 to more than $2.8 billion by the end of the forecast period, representing a compound annual growth rate (CAGR) of 3.9%. 19 June 2014
Pharmaceutical
Canadian drugmaker Valeant Pharmaceuticals International’s US subsidiary has received approval from the US Food and Drug Administration for its New Drug Application for Jublia (efinaconazole 10% topical solution), for the treatment of onychomycosis of the toenails. 9 June 2014
Pharmaceutical
USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the company announced that The Lancet Infectious Diseases has published online the positive results from ESTABLISH-2, a pivotal Phase III clinical trial of the investigational antibiotic Sivextro (tedizolid phosphate). 6 June 2014
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze